Progressive pulmonary fibrosis is not a diagnosis so much as a disease behavior and a clinical phenotype, says Anna-Maria ...

Pirfenidone use in patients with idiopathic pulmonary fibrosis may be linked to a lower incidence of lung cancer. Learn more.

The new chief medical officer of the Pulmonary Fibrosis Foundation speaks about patients in rural areas, research ...

Keep this leaflet with the medicine. You may need to read it again. Esbriet contains the active ingredient pirfenidone. Esbriet is used to treat Idiopathic Pulmonary Fibrosis (IPF). IPF is a ...

For treating pulmonary fibrosis, presently the pharmacological arsenal involves only two drugs, pirfenidone and nintedanib, which work to slow down the disease progression but do not completely ...

Dysbiosis is the condition of having imbalances in the microbial communities either in or on the body. Dysbiosis is associated with many diseases, such as inflammatory bowel disease and chronic ...

Dublin, Feb. 18, 2025 (GLOBE NEWSWIRE) -- The "Pirfenidone (CAS 53179-13-8) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029" report has been added to ...

The product has been replaced with a new NDC number. Pirfenidone: Genetech has discontinued the 267-milligram presentation of pirfenidone capsule used for pulmonary/allergy treatments ...

1 Stony Brook Cancer Center and Department of Pathology, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY, United States 2 Department of Genomic Medicine, The University of ...

Based on drug type, the pirfenidone segment accounted for the highest share in 2020, holding around three-fourths of the global idiopathic pulmonary fibrosis market, and is expected to continue its ...

Based on drug type, the pirfenidone segment accounted for the highest share in 2020, holding around three-fourths of the global idiopathic pulmonary fibrosis market, and is expected to continue ...